Overview
Dermatosparaxis Ehlers-Danlos syndrome (dEDS), formerly known as Ehlers-Danlos syndrome type VIIC, is an extremely rare heritable connective tissue disorder characterized by extreme skin fragility and laxity. The name 'dermatosparaxis' derives from Greek and Latin roots meaning 'tearing of skin.' This condition is caused by biallelic pathogenic variants in the ADAMTS2 gene, which encodes procollagen I N-proteinase, an enzyme essential for proper processing of type I procollagen into mature collagen fibrils. Without functional enzyme activity, collagen fibrils have an abnormal, hieroglyphic-like appearance on electron microscopy, leading to severely compromised connective tissue integrity. The condition primarily affects the skin, which is extremely fragile, soft, and doughy, with marked bruisability and sagging, redundant folds. Skin tears and wounds occur with minimal trauma, though wound healing is not typically severely impaired. Other characteristic features include large fontanelles and wide cranial sutures at birth, blue sclerae, micrognathia, short stature, joint hypermobility, umbilical or inguinal hernias, and premature rupture of fetal membranes. Affected individuals may also develop gingival hyperplasia and delayed closure of fontanelles. Unlike some other forms of Ehlers-Danlos syndrome, vascular complications and severe joint instability are generally less prominent, though careful monitoring is still warranted. There is currently no cure or specific disease-modifying therapy for dermatosparaxis EDS. Management is supportive and multidisciplinary, focusing on skin protection to minimize trauma, careful wound management, monitoring for hernias, and orthopedic surveillance for joint-related complications. Protective clothing and padding may help reduce skin injuries. Genetic counseling is recommended for affected families. Fewer than 30 cases have been reported in the medical literature worldwide, making this one of the rarest subtypes of Ehlers-Danlos syndrome.
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Dermatosparaxis Ehlers-Danlos syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Dermatosparaxis Ehlers-Danlos syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Dermatosparaxis Ehlers-Danlos syndrome.
Community
No community posts yet. Be the first to share your experience with Dermatosparaxis Ehlers-Danlos syndrome.
Start the conversation →Latest news about Dermatosparaxis Ehlers-Danlos syndrome
No recent news articles for Dermatosparaxis Ehlers-Danlos syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Dermatosparaxis Ehlers-Danlos syndrome
What is Dermatosparaxis Ehlers-Danlos syndrome?
Dermatosparaxis Ehlers-Danlos syndrome (dEDS), formerly known as Ehlers-Danlos syndrome type VIIC, is an extremely rare heritable connective tissue disorder characterized by extreme skin fragility and laxity. The name 'dermatosparaxis' derives from Greek and Latin roots meaning 'tearing of skin.' This condition is caused by biallelic pathogenic variants in the ADAMTS2 gene, which encodes procollagen I N-proteinase, an enzyme essential for proper processing of type I procollagen into mature collagen fibrils. Without functional enzyme activity, collagen fibrils have an abnormal, hieroglyphic-lik
How is Dermatosparaxis Ehlers-Danlos syndrome inherited?
Dermatosparaxis Ehlers-Danlos syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Dermatosparaxis Ehlers-Danlos syndrome typically begin?
Typical onset of Dermatosparaxis Ehlers-Danlos syndrome is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Dermatosparaxis Ehlers-Danlos syndrome?
7 specialists and care centers treating Dermatosparaxis Ehlers-Danlos syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.